Pyridoclax is an inhibitor of potential Mcl-1.

Pyridoclax directly binds to Mcl-1. Pyridoclax induces apoptosis in combination with Bcl-xL-targeting siRNA or with ABT-737 in ovarian, lung, and mesothelioma cancer cells. Pyridoclax causes apoptosis in ovarian, and also in lung, and mesothelioma cancer cells when it is administrated in combination with Bcl-xL-targeting siRNA or Bcl-xL targeting molecules such as ABT-737 or its orally available derivative ABT-263. Pyridoclax sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies [1][2].

1651890-44-6

C29H22N4

426.51

MR-29072

DMSO:20 mg/mL (46.89 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years